China’s NMPA Conditionally Approves Bristol Myers Squibb’s Aipodumide Hydrochloride Capsules

This is a notable regulatory win for Bristol Myers Squibb in China, where conditional approval via priority review signals both unmet need and a willingness to accelerate access for a Class 1 innovative drug. The indication's specificity — patients already exposed to a proteasome inhibitor and an immunomodulator — places it in a crowded but clinically demanding later-line myeloma space, where combination regimens increasingly compete on tolerability and sequencing rather than novelty alone. Whether the conditional status converts to full approval, and how the triplet is positioned against existing daratumumab-based combinations in Chinese clinical practice, are the questions worth tracking.